文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 医药卫生 > 基础医学 > In vitro target validation and in vivo efficacy of p38 MAP kinase inhibition in established chronic
侵权投诉

In vitro target validation and in vivo efficacy of p38 MAP kinase inhibition in established chronic

In vitro target validation and in vivo efficacy of p38 MAP kinase inhibition in established chronic collagen-induced arthritis model a pre-clinical study

To assess release of cytokines and chemokines, HUVEC were stimulated for 24 hours with 10ng/ml Fig. 6. Differential effects of GW856553X on endothelial in ammatory responses.

TNF-1, ((d) Endothelial migration was assessed using 8.0b) IL-6 and (α in the absence or presence of 100nM GW856553X (or DMSO as vehicle). Release of (c) IL-8 was measured by ELISA. Dashed line shows release from unstimulated cells. a) MCP-were GW856553X (100nM) was added to the upper and lower chambers 30 minutes prior to addition of allowed to migrate for 6 hours in response μm gelatinised polycarbonate membranes. HUVEC to 10ng/ml VEGF (or medium alone as control). VEGF (using DMSO as vehicle). All data are means ± SD, from a single experiment, representative of 3 similar experiments, and were analysed by 1-way ANOVstimulus alone: **p<0.01, p<0.001.

A versus HUVEC in the presence of To date, it remains to be de ned which stimulus and of the regulatory capacities of IL-autoimmune in ammation and wheth-induces TNF expression in 10 and Th2 cells in Th1-driven in am-er p38 MAPK controls TNF production mation, induced by this stimulus.

be associated with some unwanted ef-p38 MAPK inhibitors might New p38 MAPK inhibitors that are un-fects on the immune system, enhancing able to cross the blood-brain barrier are rather than ameliorating the underlying now in clinical trials in RA and may de-in ammatory lineate diseases. MAPK more autoimmune In contrast response in Th1-driven matory diseases. These new molecules in Th1-driven precisely the chronic role in am-of p38 ders are mediated by Th2 cells through disorders, to allergic Th1-mediated disor-have helped to clarify the role of the production of IL-4, IL-5, and IL-13. MAPK Indeed, anisms by which p38 MAPK controls, in vitro and to de ne the mech-p38 ovalbumin-induced it has been shown for example, LPS-induced cytokine ex-tion model, eosinophilia was decreased airway that in amma-in the pression in macrophages (26). The cur-by inhibition of p38 MAPK in mice (27) rent study has an advantage over these and guinea-pigs (28, 29). However, its previous reports in that these inhibitors precise can easily cross the blood-brain bar-tory processes, such as those mediating function in chronic in amma-rier towards the CNS (5). However, in autoimmune view remains unclear. The speci city of the diseases, including RA, the essential role of p38 MAPK in IL-of recent advances underlining 4 10 expression and in Th2 cell function, the substrate, namely transcription fac-different isoforms of p38 MAPK to tors and protein kinases (30), is provid-183

ed by a docking motif which is usually composed gion, the LXL motif, and the hydropho-of 3 domains: the basic re-bic importance for the determination of the region with the latter of particular p38 The development of models to predict MAPK substrate speci city (31). p38 ties may permit the design of inhibitory MAPK docking-domain speci ci-peptides of to block to block speci c pathways mediated by speci c subsets the of phosphorylation substrates so as p38 MAPK.

In our study in order to assess the effects of ined the effect of once daily dosing of p38 MAPK inhibition, we exam-GW856553X and demonstrated that this schedule is suf cient to provide ef cacy in both GW856553X and the related com-the acute CIA model. Furthermore, pound GSK678361 showed good ef ca-cy in the chronic model of CIA which is considered to more closely re ect RA. GW856553X is a novel compound rst tested arthritis models, while GSK678361 is a in chronic joint in ammation in newly both exhibit p38 MAPK inhibition with pro led benchmark compound, higher selectivity to other kinases, pro-teins chronic CIA model, therapeutic dosing or receptors. Importantly, in the with GSK678361 14 days after the on-set clinical signs of arthritis until the end of of arthritis was adequate to reduce the tions in disease achieved in response to study. The observation that reduc-therapeutic dosing were comparable to the ceived levels supported by the histopathological nd-the seen treatment in the at group the onset which was re-ings. Mechanism of action studies dem-onstrated human in endothelial that GW856553X inhibited tory vitroand MCP-1). More importantly, in our cytokine , and reduced cell production pro-in amma-angiogenesis (IL-6, IL-8 animal studies in both models, acute and chronic CIA, mice had well tolerated the administration of both compounds, and their ef cacy in the selected dosing re-gime was not compromised by any ob-served clinical side-effects as the mouse weight was unaffected (data not shown). Compounds of similar chemical class to GW856553X been used in human clinical trials with a

In vitro target validation and in vivo efficacy of p38 MAP kinase inhibition in established chronic

and GSK678361 have low incidence of side effects or toxicity

上一页第8页

你可能喜欢

热门文档

相关文档

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email